| |
Overall Cohort (n = 96)
|
Definitive SBRT Subgroup (n = 89)
|
|---|
| |
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
|---|
| |
p
|
HR (95% CI)
|
p
|
HR (95% CI)
|
p
|
HR (95% CI)
|
p
|
HR (95% CI)
|
|---|
|
PET-CT Planning
|
0.042
|
0.48 (0.23, 0.98)
|
0.042
|
0.48 (0.23, 0.98)
|
0.012
|
0.40 (0.19, 0.82)
|
0.009
|
0.40 (0.19, 0.79)
|
|
Tumor volume (5 cc increase)
|
0.415
|
0.98 (0.92, 1.03)
|
0.323
|
Not entered
|
0.514
|
0.98 (0.92, 1.04)
|
0.605
|
Not entered
|
|
Cetuximab with SBRT
|
0.304
|
0.70 (0.35, 1.39)
|
0.337
|
Not entered
|
0.089
|
0.54 (0.27, 1.10)
|
0.066
|
0.51 (0.25, 1.04)
|
|
Interval from previous radiation to recurrence (3 months increase)
|
| |
0.512
|
0.99 (0.96, 1.02)
|
0.604
|
Not entered
|
0.596
|
0.99 (0.96, 1.02)
|
0.963
|
Not entered
|
- Abbreviations: SBRT = stereotactic body radiation therapy, HR = hazard ratio for failure, CI = confidence interval.
